189 related articles for article (PubMed ID: 25647262)
21. Knockdown of kinesin family member 4A inhibits cell proliferation, migration, and invasion while promoting apoptosis of urothelial bladder carcinoma cells.
Zhang C; Wang M; Ying Y; Meng F; Gao H; Zeng S; Zhu Y; Liu A; Zhang Z; Xu C
Cancer Med; 2023 Jun; 12(11):12581-12592. PubMed ID: 37039264
[TBL] [Abstract][Full Text] [Related]
22. Down-regulated expressed protein HMGB3 inhibits proliferation and migration, promotes apoptosis in the placentas of fetal growth restriction.
Lv Y; Lv M; Ji X; Xue L; Rui C; Yin L; Ding H; Miao Z
Int J Biochem Cell Biol; 2019 Feb; 107():69-76. PubMed ID: 30543931
[TBL] [Abstract][Full Text] [Related]
23. Regulation of HMGB3 by antitumor miR-205-5p inhibits cancer cell aggressiveness and is involved in prostate cancer pathogenesis.
Yamada Y; Nishikawa R; Kato M; Okato A; Arai T; Kojima S; Yamazaki K; Naya Y; Ichikawa T; Seki N
J Hum Genet; 2018 Feb; 63(2):195-205. PubMed ID: 29196733
[TBL] [Abstract][Full Text] [Related]
24. CBX7 suppresses urinary bladder cancer progression via modulating AKR1B10-ERK signaling.
Huang Z; Yan Y; Zhu Z; Liu J; He X; Dalangood S; Li M; Tan M; Cai J; Tang P; Huang R; Shen B; Yan J
Cell Death Dis; 2021 May; 12(6):537. PubMed ID: 34035231
[TBL] [Abstract][Full Text] [Related]
25. Targeting the High-Mobility Group Box 3 Protein Sensitizes Chemoresistant Ovarian Cancer Cells to Cisplatin.
Mukherjee A; Huynh V; Gaines K; Reh WA; Vasquez KM
Cancer Res; 2019 Jul; 79(13):3185-3191. PubMed ID: 31061066
[TBL] [Abstract][Full Text] [Related]
26. MicroRNA-148a represents an independent prognostic marker in bladder cancer.
Ma L; Xu Z; Xu C; Jiang X
Tumour Biol; 2016 Jun; 37(6):7915-20. PubMed ID: 26700670
[TBL] [Abstract][Full Text] [Related]
27. Overexpression of long non-coding RNA TUG1 predicts poor prognosis and promotes cancer cell proliferation and migration in high-grade muscle-invasive bladder cancer.
Iliev R; Kleinova R; Juracek J; Dolezel J; Ozanova Z; Fedorko M; Pacik D; Svoboda M; Stanik M; Slaby O
Tumour Biol; 2016 Oct; 37(10):13385-13390. PubMed ID: 27460088
[TBL] [Abstract][Full Text] [Related]
28. Increased expression of SPRY4-IT1 predicts poor prognosis and promotes tumor growth and metastasis in bladder cancer.
Zhao XL; Zhao ZH; Xu WC; Hou JQ; Du XY
Int J Clin Exp Pathol; 2015; 8(2):1954-60. PubMed ID: 25973088
[TBL] [Abstract][Full Text] [Related]
29. Aberrant TIMELESS expression is associated with poor clinical survival and lymph node metastasis in early-stage cervical carcinoma.
Zhang W; He W; Shi Y; Zhao J; Liu S; Zhang F; Yang J; Xie C; Zhang Y
Int J Oncol; 2017 Jan; 50(1):173-184. PubMed ID: 27909716
[TBL] [Abstract][Full Text] [Related]
30. HMGB3 characterization in gastric cancer.
Gong Y; Cao Y; Song L; Zhou J; Wang C; Wu B
Genet Mol Res; 2013 Dec; 12(4):6032-9. PubMed ID: 24338397
[TBL] [Abstract][Full Text] [Related]
31. Serum Dickkopf-1 levels as a clinical and prognostic factor in patients with bladder cancer.
Sun DK; Wang L; Wang JM; Zhang P
Genet Mol Res; 2015 Dec; 14(4):18181-7. PubMed ID: 26782465
[TBL] [Abstract][Full Text] [Related]
32. Prognostic role of microRNA-100 in patients with bladder cancer.
Cao YH; Zhang HH; Xu HF; Duan YJ; Li Q; Huang B
Genet Mol Res; 2015 Dec; 14(4):15948-54. PubMed ID: 26662386
[TBL] [Abstract][Full Text] [Related]
33. Overexpression of LAMC2 predicts poor prognosis in colorectal cancer patients and promotes cancer cell proliferation, migration, and invasion.
Huang D; Du C; Ji D; Xi J; Gu J
Tumour Biol; 2017 Jun; 39(6):1010428317705849. PubMed ID: 28653882
[TBL] [Abstract][Full Text] [Related]
34. Endothelin-1 overexpression: a potential biomarker of unfavorable prognosis in non-metastatic muscle-invasive bladder cancer.
Mitrakas L; Gravas S; Karasavvidou F; Dimakopoulos G; Moutzouris G; Tzortzis V; Koukoulis G; Papandreou C; Melekos M
Tumour Biol; 2015 Jun; 36(6):4699-705. PubMed ID: 25627007
[TBL] [Abstract][Full Text] [Related]
35. Overexpression of NKX6.1 is closely associated with progressive features and predicts unfavorable prognosis in human primary hepatocellular carcinoma.
Huang LL; Zhang Y; Zhang JX; He LJ; Lai YR; Liao YJ; Tian XP; Deng HX; Liang YJ; Kung HF; Xie D; Zhu SL
Tumour Biol; 2015 Jun; 36(6):4405-15. PubMed ID: 25596704
[TBL] [Abstract][Full Text] [Related]
36. Predictive significance of combined LAPTM4B and VEGF expression in patients with cervical cancer.
Meng F; Tan S; Liu T; Song H; Lou G
Tumour Biol; 2016 Apr; 37(4):4849-55. PubMed ID: 26526574
[TBL] [Abstract][Full Text] [Related]
37. Prognostic value of miR-26a and HMGA1 in urothelial bladder cancer.
Lin R; Shen W; Zhi Y; Zhou Z
Biomed Pharmacother; 2014 Oct; 68(8):929-34. PubMed ID: 25455159
[TBL] [Abstract][Full Text] [Related]
38. CXCL5 is a potential diagnostic and prognostic marker for bladder cancer patients.
Zhu X; Qiao Y; Liu W; Wang W; Shen H; Lu Y; Hao G; Zheng J; Tian Y
Tumour Biol; 2016 Apr; 37(4):4569-77. PubMed ID: 26503215
[TBL] [Abstract][Full Text] [Related]
39. SOX9 and HMGB3 co-operatively transactivate NANOG and promote prostate cancer progression.
Xu Y; Xu M; Li X; Weng X; Su Z; Zhang M; Tan J; Zeng H; Li X; Nie L; Gong J; Chen N; Chen X; Zhou Q
Prostate; 2023 Apr; 83(5):440-453. PubMed ID: 36541373
[TBL] [Abstract][Full Text] [Related]
40. MicroRNA-31 functions as a tumor suppressor and increases sensitivity to mitomycin-C in urothelial bladder cancer by targeting integrin α5.
Xu T; Qin L; Zhu Z; Wang X; Liu Y; Fan Y; Zhong S; Wang X; Zhang X; Xia L; Zhang X; Xu C; Shen Z
Oncotarget; 2016 May; 7(19):27445-57. PubMed ID: 27050274
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
